Prof. Dr. Hans-Peter Hartung

Research Interest

Pathogenesis of autoimmune diseases of the central and peripheral nervous system (MS, GBS, CIDP) and their animal models and design and exploration of  experimental therapies. Development of regenerative therapies for inflammatory, ischemic and traumatic insults to the nervous system. Development of new immunomodulatory therapies for MS, GBS, CIDP and identification of biomarkers of diease activity, prognosis, therapeutic response.

Selected Publications

1. Aktas, O., Kieseier. B., Hartung, H.-P. (2010). Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis. Trends Neurosci. 33:140-152. undefinedPubMed

2. Cohen, J. A., Barkhof, F., Comi, G., Hartung, H.-P., Khatri, B. O., Montalban, X., Pelletier, J., Capra, R., Gallo, P., Izquierdo, G., Tiel-Wilck, K., de, V. A., Jin, J., Stites, T., Wu, S., Aradhye, S., Kappos, L. (2010). Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 362:402-415. undefinedPubMed

3. Kremer, D., Heinen, A., Jadasz, J., Göttle, P., Zimmermann, K., Zickler, P., Jander, S., Hartung, H.-P., Küry, P. (2009). p57kip2 is dynamically regulated in experimental autoimmune encephalomyelitis and interferes with oligodendroglial maturation. Proc. Natl. Acad. Sci. USA 106:9087-9092. undefinedPubMed

4. Heinen, A., Kremer, D., Göttle, P., Kruse, F., Hasse, B., Lehmann, H., Hartung, H.-P., Küry, P. (2008). The cyclin-dependent kinase inhibitor p57kip2 is a negative regulator of Schwann cell differentiation and in vitro myelination. Proc. Natl. Acad. Sci. USA 105:8748-8753. undefinedPubMed

5. Zohren, F., Toutzaris, D., Klarner, V., Hartung, H.-P., Kieseier, B., Haas, R. (2008). The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood 111:3893-3895. undefinedPubMed

6. Hartung, H.-P., Gonsette, R., König, N., Kwiecinski, H., Guseo, A., Morrissey, S. P., Krapf, H., Zwingers, T.; Mitoxantrone in Multiple Sclerosis Study Group (MIMS) (2002). Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360:2018-2025. undefinedPubMed

7. Previtali, S. C., Archelos, J. J., Hartung, H.-P. (1997). Modulation of the expression of integrins on glial cells during experimental autoimmune encephalomyelitis. A central role for TNF-alpha. Am. J. Pathol. 151:1425-1435. undefinedPubMed

8. Hartung, H.-P., Reiners, K., Archelos, J. J., Michels, M., Seeldrayers, P., Heidenreich, F., Pflughaupt, K. W., Toyka, K. V. (1995). Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging. Ann. Neurol. 38:186-193. undefinedPubMed

9. Pollard, J. D., Westland, K. W., Harvey, G. K., Jung, S., Bonner, J., Spies, J. M., Toyka, K. V., Hartung, H.-P. (1995). Activated T cells of nonneural specificity open the blood-nerve barrier to circulating antibody. Ann. Neurol. 37:467-475. undefinedPubMed

10. Archelos, J. J., Jung, S., Mäurer, M., Schmied, M., Lassmann, H., Tamatani, T., Miyasaka, M., Toyka, K. V., Hartung, H.-P. (1993). Inhibition of experimental autoimmune encephalomyelitis by an antibody to the intercellular adhesion molecule ICAM-1. Ann. Neurol. 34:145-154. undefinedPubMed

Prof. Dr.
Hans-Peter Hartung

Direktor der Neurologischen Klinik

Prof. Dr. Hans-Peter Hartung

Department of Neurology
Heinrich Heine University
Moorenstraße 5
40225 Düsseldorf

Tel.: +49 211 81-17880
Fax: +49 211 81-18469
Verantwortlich für den Inhalt: E-Mail sendenNeuroscience Network Düsseldorf